Skip to main content

Table 2 Distribution of phage types, multidrug resistance, PFGE profiles and MLVA types among the 375 STM isolates from the domestic infections

From: Characterization of Salmonella Typhimurium isolates from domestically acquired infections in Finland by phage typing, antimicrobial susceptibility testing, PFGE and MLVA

Phage type

No. Isolates ( % of total)

MDRa (No. of isolates)

No. PFGE profiles within one phage type

The most common PFGE profiles (number of strains, %)

No. MLVA profiles within one phage type

The most common MLVA profiles (number of strains, %)

DT1

180 (48 %)

ASSuTm (1)

23

STYM1 (140, 77 %)

20

3-16-NA-NA-0311 (105, 58 %)

STYM100 (5, 3 %)

3-15-NA-NA-0311 (23, 13 %)

STYM262 (4, 2 %)

3-18-NA-NA-0311 (8, 4 %)

U277

33 (9 %)

-

7

STYM8 (26, 79 %)

7

3-16-NA-NA-0311 (14, 42 %)

STYM265 (3, 9 %)

3-16-NA-NA-0211 (6, 18 %)

3-18-NA-NA-0311 (6, 18 %)

DT104

32 (8 %)

ACSSuTNx (14), ACSSuT (3)

7

STYM7 (24, 75 %)

18

3-13-5-12-0311 (11, 34 %)

STYM47 (3, 9 %)

3-14-16-21-0311 (3, 9 %)

DT116

14 (4 %)

ASuTTm (2), ASSuT (1)

6

STYM243 (6, 42 %)

7

5-14-NA-NA-0611 (6, 42 %)

STYM275, (3, 21 %)

2-19-NA-NA-0211 (3, 21 %)

DT120

11 (3 %)

ACSSuT (1), SSSuT (1)

7

STYM194 (3, 27 %)

8

3-12-9-NA-0211 (3, 27 %)

    

STYM154 (3, 27 %)

 

2-13-NA-NA-0311 (2, 18 %)

DT41

12 (3 %)

-

5

STYM52 (7, 58 %)

11

3-16-NA-NA-0311 (2, 16 %)

STYM1 (2, 16 %)

DT104B

10 (3 %)

ACSSuT (4), ASSuT (4),

5

STYM7 (5, 50 %)

10

10 individual profiles

ACSSuTTm (1), CSSuTGNx (1)

RDNC4

9 (2 %)

-

2

STYM42 (8, 89 %)

3

3-17-NA-NA-0311 (7, 78 %)

RDNC2

6 (2 %)

-

2

STYM8 (3, 50 %)

3

3-14-NA-NA-0311 (3, 50 %)

STYM265 (3, 50 %)

3-15-NA-NA-0311 (2, 33 %)

DT2

6 (2 %)

-

2

STYM141 (5, 83 %)

3

2-14-12-8-0212 (4, 67 %)

DT193

6 (2 %)

ACSSuT (1), ASuTTm (1), ASSuT (1)

6

6 individual profiles

6

6 individual profiles

DT195

5 (1 %)

-

4

STYM8 (2, 40 %)

5

5 individual profiles

DT12

4 (<1 %)

-

3

STYM238 (2, 50 %)

2

4-13-9-7-211 (3, 75 %)

U282

4 (<1 %)

 

3

STYM42 (2, 50 %)

3

3-16-NA-NA-311 (2, 50 %)

U302

4 (<1 %)

ACSSuT (1)

2

STYM228 (3, 75 %)

2

2-15-NA-NA-211 (3, 75 %)

RDNC1

3 (<1 %)

-

1

STYM124 (3, 100 %)

3

3 individual profiles

DT8

2 (<1 %)

-

2

2 individual profiles

2

2 individual profiles

DT9

2 (<1 %)

-

1

STYM285 (2, 100 %)

2

2 individual profiles

U311

2 (<1 %)

ACSSuTTmNx (1), ASuTNx (1)

2

2 individual profiles

2

2 individual profiles

U312

2 (<1 %)

-

1

STYM119 (2, 100 %)

2

2 individual profiles

RDNC3

2 (<1 %)

-

2

2 individual profiles

2

2 individual profiles

RDNC5

2 (<1 %)

-

1

STYM8 (2, 100 %)

2

2 individual profiles

DT7

1

-

1

 

1

 

DT10

1

-

1

 

1

 

DT15A

1

-

1

 

1

 

DT40

1

-

1

 

1

 

DT99

1

-

1

 

1

 

DT132

1

-

1

 

1

 

DT135

1

-

1

 

1

 

NT

1

-

1

 

1

 

RDNC

16 induvidual phage reactions

ACSuTTm (1), ASSUT (1)

14

STYM1 (2, 14 %)

14

3-16-NA-NA-0311 (2, 14 %)

31 individual phage types

total 375 isolates

43 multiresistant isolates

83 individual PFGE types

 

115 individual MLVA types

 
  1. DT, Definite phage type
  2. RDNC, Reacts but does not confirm
  3. NT, Not typeable
  4. MDR, Multidrug resistance, a only R counted as resistance (I not included)
  5. Antimicrobials: ampicillin (A), chloramphenicol (C), streptomycin (S), sulphonamide (Su), tetracycline (T), trimethoprim (Tm), gentamicin (G), nalidixic acid (Nx)
  6. PFGE, Pulsed-field gel electrophoresis
  7. MLVA, Multilocus variable-number tandem repeat analysis
  8. NA, No amplification